Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DAB2IP
REST API REST API
Homo sapiens
DAB2IP is differentially expressed in 140 experiments: 83 organism parts: bone marrow, cerebellum, ... (81 more);, 79 disease states: normal, prostate carcinoma, ... (77 more);, 49 cell types 361 cell lines 16 compound treatments and 48 other conditions.
Synonyms AIP1, AF9Q34, KIAA1743, DIP1/2
Orthologs Dab2ip (Mus musculus)   DAB2IP (Gallus gallus)   Dab2ip (Rattus norvegicus)   DAB2IP (Bos taurus)   CG42684 (Drosophila melanogaster)   B0BMG0_XENTR (Xenopus laevis)   DAB2IP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Ras GTPase activator activity, plasma membrane, negative regulation of cell growth, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, cytoplasm, intracellular, protein N-terminus binding, negative regulation of Ras protein signal transduction, positive regulation of apoptosis, positive regulation of JUN kinase activity, protein phosphatase 2A binding, GTPase activator activity, positive regulation of transcription from RNA polymerase II promoter, activation of JUN kinase activity, protein kinase binding, regulation of small GTPase mediated signal transduction, protein homodimerization activity, negative regulation of MAP kinase activity, negative regulation of transcription from RNA polymerase II promoter, negative regulation of epithelial cell proliferation, negative regulation of fibroblast proliferation, negative regulation of NF-kappaB transcription factor activity, positive regulation of Ras GTPase activity, negative regulation of epithelial to mesenchymal transition, negative regulation of epithelial cell migration, negative regulation of I-kappaB kinase/NF-kappaB cascade, death receptor binding, negative regulation of Ras GTPase activity, apoptosis in response to endoplasmic reticulum stress, cellular response to tumor necrosis factor, positive regulation of signal transduction, negative regulation of canonical Wnt receptor signaling pathway, mitogen-activated protein kinase kinase kinase binding, intrinsic to internal side of plasma membrane, signaling adaptor activity, negative regulation of protein serine/threonine kinase activity, 14-3-3 protein binding, positive regulation of protein serine/threonine kinase activity, cellular response to epidermal growth factor stimulus, negative regulation of catenin import into nucleus
InterPro Term C2_Ca-dep, Pleckstrin_homology, RasGAP, DUF3498
UniProt Accession B5MDY7, B3KW96, B0QZB2, B0QZ97, Q5VWQ7, Q5VWQ8, F6R503, F8WA47
Search EB-eye ENSG00000136848
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-GEOD-6919, E-TABM-130, ... (13 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, ... (22 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MKN7
1
E-GEOD-15460
NCIH82
1
E-MTAB-37
DMS114
1
E-MTAB-37
NCIH2122
1
E-MTAB-37
355 more value(s).


Cell type

studied in E-GEOD-18811, E-AFMX-5, E-GEOD-19069, E-GEOD-22373, E-MEXP-1121, ... (23 experiments)

Factor Value U/D Experiments
cardiac myocyte
1
E-AFMX-5
epithelial cell
1
E-MEXP-1121
testis - leydig cell
1
E-AFMX-5
liver cancer
1
E-GEOD-21154
neutrophil
1
E-GEOD-12662
T-ALL
1
E-GEOD-19069
43 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-MEXP-1121, E-GEOD-16363, E-GEOD-9692, ... (32 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-37, E-GEOD-7307
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
nodal peripheral T-cell lymphoma
1
E-TABM-702
Parkinson's disease
1
E-GEOD-7307
rhabdomyosarcoma
1
E-MTAB-37
acute HIV-1 infection
1
E-GEOD-16363
73 more value(s).


Compound treatment

studied in E-GEOD-3284, E-MEXP-2218, E-GEOD-15205, E-TABM-782, E-TABM-127, ... (9 experiments)

Factor Value U/D Experiments
none
2
E-TABM-868, E-TABM-782
CNOT7+CNOT8
1
1
E-MEXP-2218
unknown
1
E-GEOD-7307
filtered air
1
E-TABM-127
Cxcl12
1
1
E-GEOD-7307
TGF
1
1
E-GEOD-15205
10 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
46
2
1
E-GEOD-3494
46 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-4667

Disease staging
studied in E-GEOD-19743

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-TABM-868, E-GEOD-17347

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-GEOD-13073, E-TABM-127, E-GEOD-20504, E-MEXP-1741, E-TABM-440 ... (5 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-TABM-176, E-MEXP-2069, E-TABM-666, E-MEXP-1648, ... (16 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-1460, E-GEOD-17636

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-6532, E-GEOD-4922

Processing time: 0.339 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM